{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00016529", "CSN": null, "TRF": "ORD_1194451_01", "MRN": "19906060", "PhysicianId": "34792", "NPI": "international"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "893342", "clinicalId": "894747", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1194451_01", "SampleName": "US1158127.01", "Version": "0", "Sample": {"FM_Id": "ORD_1194451_01", "SampleId": "US1158127.01", "BlockId": "S109-16673C", "TRFNumber": "ORD_1194451_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2021_09_28", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-99718", "MRN": "19906060", "FullName": "\u7c21\u9e97\u6dd1", "FirstName": "Li_Shu", "LastName": "Chien", "SubmittedDiagnosis": "Metastatic carcinoma, Lung", "Gender": "Female", "DOB": "1966_12_01", "OrderingMD": "\u5f35\u7267\u65b0", "OrderingMDId": "34792", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2020_06_05", "ReceivedDate": "2021-10-07 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Carcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "9", "clinicalTrialCount": "18", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "ABL1", "isVUS": "true", "variantName": "T984M"}, {"geneName": "AKT1", "isVUS": "true", "variantName": "R174H"}, {"geneName": "MSH6", "isVUS": "true", "variantName": "K1358fs*2"}, {"geneName": "SETD2", "isVUS": "true", "variantName": "P190L"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "G1286W"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CHEK2", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 2_10", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 2_10"}}, "Interpretation": "CHEK2 encodes the protein checkpoint kinase 2, a serine/threonine kinase that plays an important role in the DNA_damage response; it is a putative tumor suppressor (Tomlinson et al., 2012; 22294770, Xu et al., 1990; 2205842, van der Groep et al., 2011; 21336636, Schutte et al., 2003; 12610780). Alterations such as seen here may disrupt CHEK2 function or expression (Xu et al., 2002; 12024051, Lee and Chung, 2001; 11390408, Schwarz et al., 2003; 12805407, Ng et al., 2003; 14681223, Matsuoka et al., 2000; 10973490, Zhou et al., 2000; 10744722, Ahn et al., 2000; 11085506, Melchionna et al., 2000; 11025670, Yoda et al., 2006; 16798742, Chehab et al., 2000; 10673500, Lee et al., 2001; 11719428). CHEK2 mutations have been reported in 8.3% of glioblastoma (GBM) samples and in carcinomas of the endometrium (3.8%), urinary tract (3.5%), ovary (3.4%), and large intestine (3.1%), and at low frequency in a variety of solid and hematologic cancer types (COSMIC, 2021)(Tate et al., 2019; 30371878). In breast cancer, certain CHEK2 mutations are associated with higher grade and larger tumors as well as bilateral disease (Kilpivaara et al., 2005; 15472904). A study reported that a polymorphism in CHEK2 was associated with worse survival of patients with GBM, but this association lost significance after adjusting for other prognostic factors (Simon et al., 2006; 17016233, Dong et al., 2014; 24532427). Another study in prostate cancer reported that CHEK2 expression is decreased in higher grade tumors and that CHEK2 is a tumor suppressor that decreases the growth of prostate cancer cells and regulates androgen receptor signaling (Ta et al., 2015; 26573794). Limited clinical data indicate that CHEK2 inactivation may predict sensitivity to PARP inhibitors. Patients with CHEK2_altered prostate cancer have experienced clinical responses to PARP inhibitors (Abida et al., 2020; 32086346, Mateo et al., 2020; 31806540, Mateo et al., 2015; 26510020). Clinical benefit has been observed for patients with ovarian (Swisher et al., 2017; 27908594, O Malley et al., 2017; AACR Abstract LB_A12) and testicular (Gruber et al., 2019; ASCO Abstract 3006) cancers treated with PARP inhibitors. One study of patients with breast cancer reported that carriers of the CHEK2 H371Y mutation have a higher likelihood of response to neoadjuvant chemotherapy (Liu et al., 2015; 25884806), whereas another study found that CHEK2 mutation carriers have a lower frequency of objective clinical responses to neoadjuvant therapy (Pfeifer et al., 2014; 25414026). A third study reported that the CHEK2 1100delC mutation is not associated with differential efficacy of chemotherapy and endocrine therapy in patients with metastatic breast cancer (Kriege et al., 2015; 25958056). Germline CHEK2 mutation has been associated with cancer susceptibility of low to moderate penetrance, especially in hereditary breast cancer (Mahdavi et al., 2019; 30552672). CHEK2 germline mutation has been identified in approximately 2.5% of familial or high_risk breast cancer cases (Kleiblov\u00e1 et al., 2019; 31409080, Hauke et al., 2018; 29522266). Although heterozygous germline CHEK2 mutation increases breast cancer risk two_ to three_fold, it is not associated with younger age at diagnosis (Hauke et al., 2018; 29522266, Lu et al., 2019; 30128536). In the appropriate clinical context, germline testing of CHEK2 is recommended.", "Include": "true", "ClinicalTrialNote": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04123366", "Include": "true"}, {"nctId": "NCT03742895", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04635631", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT02769962", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT03127215", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "SMARCB1", "Include": "true", "Alterations": {"Alteration": {"Name": "loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss"}}, "Interpretation": "The SMARCB1 gene encodes the SNF5 protein, also known as INI1, one of three core subunits of the SWI/SNF family of chromatin remodeling complexes (Wilson and Roberts, 2011; 21654818). SNF5, as a member of the remodeling complex, plays a key role in cell cycle control and can act as a tumor suppressor (Versteege et al., 2002; 12226744). Alterations such as seen here may disrupt SMARCB1 function or expression (Morozov et al., 1998; 9448295, Das et al., 2009; 19398554, Zhang et al., 2002; 12138206, Valencia et al., 2019; 31759698, Kondelin et al., 2018; 30108113, Vries et al., 2005; 15769941). The loss of SMARCB1 protein expression was reported in 6% of 142 sinonasal carcinomas in another study, with genomic loss of SMARCB1 identified in 75% (6/8) of patients in that subset (Bishop et al., 2014; 25007146). In a genomic analysis of 56 nasopharyngeal carcinoma cases, alterations of SMARCB1 was not detected in any of the samples (cBio_Lin et al., 2014; 24952746). Loss of SMARCB1 has been reported in all three sinonasal basaloid carcinomas analyzed in one study (Agaimy et al., 2014; 24832165). In head and neck carcinoma, SMARCB1 inactivation may indicate an INI1_deficient subtype of sinonasal carcinoma characterized by poor differentiation and aggressive clinicopathologic features (Kakkar et al., 2019; 30120966, Agaimy et al., 2017, 28291122, Bishop et al., 2014; 25007146). Clinical and preclinical evidence suggests that tumors with loss of SMARCB1 may be sensitive to a variety of targeted therapies, including EZH2 inhibitors (Gounder et al., 2020; 33035459, Italiano et al., 2018; 29650362, Alimova et al., 2013; 23190500, Knutson et al., 2013; 23620515), CDK4/6 inhibitors (Alarcon_Vargas et al., 2006; 16302003, Smith et al., 2011; 21173237, Geoerger et al., 2017; 28432176, Hashizume et al., 2016; 27370397), Aurora kinase inhibitors (Lee et al., 2011; 21521802), and anti_PD_1 immune checkpoint inhibitors (Forrest et al., 2020; 32122923, Leruste et al., 2019; 31708437, Chun et al., 2019; 31708418, Panwalkar et al., 2020; 31912158). The EZH2 inhibitor tazemetostat has shown efficacy in adult and pediatric patients with INI1_negative solid tumors across Phase 1 and 2 trials, predominantly in sarcoma subtypes (Gounder et al., 2020; 33035459, Stacchiotti et al., 2018; ESMO Abstract 1611PD, Chi et al., 2017; AACR_NCI_EORTC Abstract 175, Italiano et al., 2015; ECC Abstract 302). A clinical trial of the Aurora kinase A inhibitor alisertib for pediatric patients with atypical teratoid rhabdoid tumors, which are characterized by SMARCB1 loss or inactivation, reported disease stabilization or regression in 100% (4/4) of patients, and 2 patients achieved disease regression lasting more than 1 year (Wetmore et al., 2015; 25688119). A study of INI1_negative pediatric solid tumors observed frequent signs of T_cell inflammation, including PD_L1 expression in 47% (14/30) of patients, and reported 3 patients with metastatic epithelioid sarcoma, anaplastic chordoma, or malignant rhabdoid tumor who experienced disease control on pembrolizumab or nivolumab for at least 12, 9, and 3 months, respectively (Forrest et al., 2020; 32122923). Case studies have reported a patient with treatment_refractory metastatic epithelioid sarcoma had a PR on nivolumab plus ipilimumab, with the addition of pazopanib leading to a CR of >12 months (Pecora et al., 2020; 32815894); a patient with SMARCB1_mutated metastatic renal medullary carcinoma (RMC) had SD for 7 months with nivolumab (Sodji et al., 2017; 28807004); and a patient with metastatic RMC and concurrent SMARCB1 loss and ARID2 mutation had a CR with 9 months of nivolumab treatment (Beckermann et al., 2017; 28105368). Preclinical evidence also supports PD_1 immune checkpoint blockade as treatment approach for rhabdoid tumors that are characterized by SMARCB1 inactivation and T_cell inflammation (Leruste et al., 2019; 31708437, Chun et al., 2019; 31708418). SMARCB1 mutation and loss of protein expression are characteristic of malignant rhabdoid tumors, INI1_deficient sinonasal carcinomas, epithelioid sarcomas, kidney medullary carcinoma and atypical teratoid/rhabdoid tumors, particularly in cases with low TMB and a paucity of co_occurring alterations (NCCN Soft Tissue Sarcoma Guidelines, v2.2021)(Forrest et al., 2020; 32122923, Hollmann and Hornick, 2011; 21934399, Oda and Tsuneyoshi, 2009; 19076980, Hasselblatt et al., 2013; 23074045, Rizzo et al., 2012; 22614000, Sullivan et al., 2013; 23060122, Arnold et al., 2013; 23245672, Hasselblatt et al., 2013; 23074045, Kakkar et al., 2019; 30120966, Agaimy et al., 2017, 28291122, Bishop et al., 2014; 25007146, Jia et al. 2019, 30980040).", "Include": "true", "ClinicalTrialNote": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Tazemetostat", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Tazemetostat is an inhibitor of the histone methyltransferase EZH2. It is FDA approved as a monotherapy for the treatment of metastatic or locally advanced epithelioid sarcoma and relapsed or refractory follicular lymphoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of Phase 2 clinical data across sarcoma subtypes and sinonasal carcinoma (Stacchiotti et al., 2019; ASCO Abstract 11003, Stacchiotti et al., 2018; ESMO Abstract 1611PD, Chi et al., 2017; AACR_NCI_EORTC Abstract A175, Italiano et al., 2018; 29650362), and preclinical evidence (Kawano et al., 2016; 27391784, Knutson et al., 2013; 23620515), loss or inactivation of SMARCB1 may predict sensitivity to tazemetostat. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of tazemetostat for the treatment of head and neck cancer are limited (PubMed, Aug 2021). In solid tumors, tazemetostat has been primarily investigated in the context of INI1_deficient sarcomas. A Phase 2 study for patients with INI1_negative tumors treated with tazemetostat reported ORRs (all PRs) of 15% (9/62) for the epithelioid sarcoma cohort (Stacchiotti et al., 2019; ASCO Abstract 11003), 0% (0/11) for the malignant rhabdoid tumor (MRT) cohort (Jones et al., 2018; ESMO Abstract 1612PD), and 9.4% (3/32) for those with other solid tumors, including PRs in 2 of 13 patients with sarcoma (both spindle cell sarcoma) and 1 of 16 patients with non_mesenchymal tumors (a sinonasal carcinoma) (Stacchiotti et al., 2018; ESMO Abstract 1611PD). For patients with synovial sarcoma, a Phase 2 study reported that treatment with tazemetostat monotherapy achieved SD as best response in 33% (11/33) of patients, with 5 SDs lasting \u226516 weeks (Schoffski et al., 2017; ASCO Abstract 11057). Additional Phase 1/2 trials for tazemetostat have reported clinical benefit for adult patients with small cell carcinoma of the ovary, hypercalcemic type (2 PRs)(Jones et al., 2018; ESMO Abstract 1612PD, Penebre et al., 2015; EORTC Abstract C87, Italiano et al., 2018; 29650362) malignant mesothelioma (2 PRs)(Zauderer et al., 2018; ASCO Abstract 8515), and MRT (1 CR)(Italiano et al., 2018; 29650362). A Phase 1 trial for 46 pediatric patients with synovial sarcoma or INI1_negative tumors reported clinical benefit in the context of epithelioid sarcoma (1 CR), chordoma (1 CR, 1PR), or atypical teratoid rhabdoid tumor (ATRT, 1 CR) across tazemetostat dosage groups (Chi et al., 2017; AACR_NCI_EORTC Abstract A175). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03099174", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04104776", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}, {"nctId": "NCT04555837", "Include": "true"}, {"nctId": "NCT04241835", "Include": "true"}, {"nctId": "NCT03065062", "Include": "true"}, {"nctId": "NCT03454035", "Include": "true"}, {"nctId": "NCT02897375", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). One retrospective study of patients with Stage 2_4a nasopharyngeal carcinoma treated with intensity_modulated radiotherapy in China reported that deficiency of mismatch repair protein expression independently correlated with better distant metastasis_free survival (HR=0.25) (Chen et al., 2020; 32546739). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Nasopharyngeal and sinonasal undifferentiated carcinoma harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 1.9% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Published data investigating the prognostic implications of TMB in nasopharyngeal and sinonasal carcinoma are limited (PubMed, Oct 2021). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)", "StudyPhase": "PHASE 2", "Target": "PARP, PD_1", "Locations": "Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)", "NCTID": "NCT04123366", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)", "NCTID": "NCT03742895", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California", "NCTID": "NCT02264678", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS", "StudyPhase": "PHASE 1", "Target": "PARP", "Locations": "Beijing (China), Changchun (China)", "NCTID": "NCT04635631", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer", "StudyPhase": "PHASE 1/2", "Target": "PARP, TOP1", "Locations": "Maryland", "NCTID": "NCT02769962", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas", "NCTID": "NCT04497116", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Study of Olaparib/Trabectedin vs. Doctor s Choice in Solid Tumors", "StudyPhase": "PHASE 2", "Target": "FUS_DDIT3, PARP", "Locations": "Dresden (Germany), M\u00fcnchen (Germany), Frankfurt (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Stuttgart (Germany), Tuebingen (Germany), Freiburg (Germany)", "NCTID": "NCT03127215", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "CHEK2", "Alteration": "loss exons 2_10", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.", "StudyPhase": "PHASE 1", "Target": "CDK4, CDK6, IGF_1, IGF_2, Aromatase, ER", "Locations": "Seoul (Korea, Republic of), Goyang (Korea, Republic of), Aichi, Nagoya (Japan), Kanagawa, Isehara (Japan), Tokyo, Chuo_ku (Japan), Tokyo, Koto_ku (Japan), Chiba, Kashiwa (Japan), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT03099174", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "A Study of CPI_0209 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "EZH2, TOP1", "Locations": "Washington, Michigan, Ohio, Massachusetts, New Jersey, Texas, Virginia, Georgia", "NCTID": "NCT04104776", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, PD_1", "Locations": "Texas", "NCTID": "NCT04555837", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies", "StudyPhase": "PHASE 1", "Target": "EZH2", "Locations": "J\u00f3zef\u00f3w (Poland), Pozna\u0144 (Poland), Bratislava (Slovakia), Edegem (Belgium), Brussels (Belgium), Lille (France), Marseille (France), Bordeaux Cedex (France), Nevada, Illinois", "NCTID": "NCT04241835", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03065062", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MAPK3, MAPK1, CDK4, CDK6", "Locations": "North Carolina", "NCTID": "NCT03454035", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "SMARCB1", "Alteration": "loss", "Title": "Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "CDK4, CDK6", "Locations": "Georgia", "NCTID": "NCT02897375", "Note": "On the basis of clinical and preclinical evidence, loss or inactivation of SMARCB1 may be associated with sensitivity to EZH2 inhibitors, CDK4/6 inhibitors, and Aurora kinase inhibitors. Patients with certain SMARCB1_deficient malignant tumors have benefited from anti_PD_1 immune checkpoint inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "22294770", "FullCitation": "Tomlinson IP, et al. Mutagenesis (2012) pmid: 22294770", "Include": "true"}, {"number": "1", "ReferenceId": "2205842", "FullCitation": "Xu HP, et al. Nucleic Acids Res. (1990) pmid: 2205842", "Include": "true"}, {"number": "2", "ReferenceId": "21336636", "FullCitation": "van der Groep P, et al. Cell Oncol (Dordr) (2011) pmid: 21336636", "Include": "true"}, {"number": "3", "ReferenceId": "12610780", "FullCitation": "Schutte M, et al. Am. J. Hum. Genet. (2003) pmid: 12610780", "Include": "true"}, {"number": "4", "ReferenceId": "12024051", "FullCitation": "Xu X, et al. Mol. Cell. Biol. (2002) pmid: 12024051", "Include": "true"}, {"number": "5", "ReferenceId": "11390408", "FullCitation": "Lee CH, et al. J. Biol. Chem. (2001) pmid: 11390408", "Include": "true"}, {"number": "6", "ReferenceId": "12805407", "FullCitation": "Schwarz JK, et al. Mol. Cancer Res. (2003) pmid: 12805407", "Include": "true"}, {"number": "7", "ReferenceId": "14681223", "FullCitation": "Ng CP, et al. J. Biol. Chem. (2004) pmid: 14681223", "Include": "true"}, {"number": "8", "ReferenceId": "10973490", "FullCitation": "Matsuoka S, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10973490", "Include": "true"}, {"number": "9", "ReferenceId": "10744722", "FullCitation": "Zhou BB, et al. J. Biol. Chem. (2000) pmid: 10744722", "Include": "true"}, {"number": "10", "ReferenceId": "11085506", "FullCitation": "Ahn JY, et al. Cancer Res. (2000) pmid: 11085506", "Include": "true"}, {"number": "11", "ReferenceId": "11025670", "FullCitation": "Melchionna R, et al. Nat. Cell Biol. (2000) pmid: 11025670", "Include": "true"}, {"number": "12", "ReferenceId": "16798742", "FullCitation": "Yoda A, et al. J. Biol. Chem. (2006) pmid: 16798742", "Include": "true"}, {"number": "13", "ReferenceId": "10673500", "FullCitation": "Chehab NH, et al. Genes Dev. (2000) pmid: 10673500", "Include": "true"}, {"number": "14", "ReferenceId": "11719428", "FullCitation": "Lee SB, et al. Cancer Res. (2001) pmid: 11719428", "Include": "true"}, {"number": "15", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "16", "ReferenceId": "15472904", "FullCitation": "Kilpivaara O, et al. Int. J. Cancer (2005) pmid: 15472904", "Include": "true"}, {"number": "17", "ReferenceId": "17016233", "FullCitation": "Simon M, et al. Neurosurgery (2006) pmid: 17016233", "Include": "true"}, {"number": "18", "ReferenceId": "24532427", "FullCitation": "Dong YS, et al. Tumour Biol. (2014) pmid: 24532427", "Include": "true"}, {"number": "19", "ReferenceId": "26573794", "FullCitation": "Ta HQ, et al. Cancer Res. (2015) pmid: 26573794", "Include": "true"}, {"number": "20", "ReferenceId": "32086346", "FullCitation": "Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346", "Include": "true"}, {"number": "21", "ReferenceId": "31806540", "FullCitation": "Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540", "Include": "true"}, {"number": "22", "ReferenceId": "26510020", "FullCitation": "Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020", "Include": "true"}, {"number": "23", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "24", "ReferenceId": "25884806", "FullCitation": "Liu Y, et al. BMC Cancer (2015) pmid: 25884806", "Include": "true"}, {"number": "25", "ReferenceId": "25414026", "FullCitation": "Pfeifer W, et al. Breast Cancer Res. Treat. (2014) pmid: 25414026", "Include": "true"}, {"number": "26", "ReferenceId": "25958056", "FullCitation": "Kriege M, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 25958056", "Include": "true"}, {"number": "27", "ReferenceId": "30552672", "FullCitation": "Mahdavi M, et al. J Cell Physiol (2019) pmid: 30552672", "Include": "true"}, {"number": "28", "ReferenceId": "31409080", "FullCitation": "Kleiblov\u00e1 P, et al. Klin Onkol (2019) pmid: 31409080", "Include": "true"}, {"number": "29", "ReferenceId": "29522266", "FullCitation": "Hauke J, et al. Cancer Med (2018) pmid: 29522266", "Include": "true"}, {"number": "30", "ReferenceId": "30128536", "FullCitation": "Lu HM, et al. JAMA Oncol (2019) pmid: 30128536", "Include": "true"}, {"number": "31", "ReferenceId": "21654818", "FullCitation": "Wilson BG, et al. Nat. Rev. Cancer (2011) pmid: 21654818", "Include": "true"}, {"number": "32", "ReferenceId": "12226744", "FullCitation": "Versteege I, et al. Oncogene (2002) pmid: 12226744", "Include": "true"}, {"number": "33", "ReferenceId": "9448295", "FullCitation": "Morozov A, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9448295", "Include": "true"}, {"number": "34", "ReferenceId": "19398554", "FullCitation": "Das S, et al. J. Biol. Chem. (2009) pmid: 19398554", "Include": "true"}, {"number": "35", "ReferenceId": "12138206", "FullCitation": "Zhang ZK, et al. Mol. Cell. Biol. (2002) pmid: 12138206", "Include": "true"}, {"number": "36", "ReferenceId": "31759698", "FullCitation": "Valencia AM, et al. Cell (2019) pmid: 31759698", "Include": "true"}, {"number": "37", "ReferenceId": "30108113", "FullCitation": "Kondelin J, et al. EMBO Mol Med (2018) pmid: 30108113", "Include": "true"}, {"number": "38", "ReferenceId": "15769941", "FullCitation": "Vries RG, et al. Genes Dev (2005) pmid: 15769941", "Include": "true"}, {"number": "39", "ReferenceId": "25007146", "FullCitation": "Bishop JA, et al. Am. J. Surg. Pathol. (2014) pmid: 25007146", "Include": "true"}, {"number": "40", "ReferenceId": "24952746", "FullCitation": "Lin DC, et al. Nat. Genet. (2014) pmid: 24952746", "Include": "true"}, {"number": "41", "ReferenceId": "24832165", "FullCitation": "Agaimy A, et al. Am. J. Surg. Pathol. (2014) pmid: 24832165", "Include": "true"}, {"number": "42", "ReferenceId": "30120966", "FullCitation": "Kakkar A, et al. Hum. Pathol. (2019) pmid: 30120966", "Include": "true"}, {"number": "43", "ReferenceId": "33035459", "FullCitation": "Gounder M, et al. Lancet Oncol (2020) pmid: 33035459", "Include": "true"}, {"number": "44", "ReferenceId": "29650362", "FullCitation": "Italiano A, et al. Lancet Oncol. (2018) pmid: 29650362", "Include": "true"}, {"number": "45", "ReferenceId": "23190500", "FullCitation": "Alimova I, et al. Neuro_oncology (2013) pmid: 23190500", "Include": "true"}, {"number": "46", "ReferenceId": "23620515", "FullCitation": "Knutson SK, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23620515", "Include": "true"}, {"number": "47", "ReferenceId": "16302003", "FullCitation": "Alarcon_Vargas D, et al. Oncogene (2006) pmid: 16302003", "Include": "true"}, {"number": "48", "ReferenceId": "21173237", "FullCitation": "Smith ME, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21173237", "Include": "true"}, {"number": "49", "ReferenceId": "28432176", "FullCitation": "Geoerger B, et al. Clin. Cancer Res. (2017) pmid: 28432176", "Include": "true"}, {"number": "50", "ReferenceId": "27370397", "FullCitation": "Hashizume R, et al. Neuro_oncology (2016) pmid: 27370397", "Include": "true"}, {"number": "51", "ReferenceId": "21521802", "FullCitation": "Lee S, et al. Cancer Res. (2011) pmid: 21521802", "Include": "true"}, {"number": "52", "ReferenceId": "32122923", "FullCitation": "Forrest SJ, et al. Clin Cancer Res (2020) pmid: 32122923", "Include": "true"}, {"number": "53", "ReferenceId": "31708437", "FullCitation": "Leruste A, et al. Cancer Cell (2019) pmid: 31708437", "Include": "true"}, {"number": "54", "ReferenceId": "31708418", "FullCitation": "Chun HE, et al. Cell Rep (2019) pmid: 31708418", "Include": "true"}, {"number": "55", "ReferenceId": "31912158", "FullCitation": "Panwalkar P, et al. Neuro Oncol (2020) pmid: 31912158", "Include": "true"}, {"number": "56", "ReferenceId": "25688119", "FullCitation": "Wetmore C, et al. Neuro_oncology (2015) pmid: 25688119", "Include": "true"}, {"number": "57", "ReferenceId": "32815894", "FullCitation": "Pecora A, et al. J Immunother () pmid: 32815894", "Include": "true"}, {"number": "58", "ReferenceId": "28807004", "FullCitation": "Sodji Q, et al. J Immunother Cancer (2017) pmid: 28807004", "Include": "true"}, {"number": "59", "ReferenceId": "28105368", "FullCitation": "Beckermann KE, et al. J Immunother Cancer (2017) pmid: 28105368", "Include": "true"}, {"number": "60", "ReferenceId": "21934399", "FullCitation": "Hollmann TJ, et al. Am. J. Surg. Pathol. (2011) pmid: 21934399", "Include": "true"}, {"number": "61", "ReferenceId": "19076980", "FullCitation": "Oda Y, et al. Cancer Sci. (2009) pmid: 19076980", "Include": "true"}, {"number": "62", "ReferenceId": "23074045", "FullCitation": "Hasselblatt M, et al. Genes Chromosomes Cancer (2013) pmid: 23074045", "Include": "true"}, {"number": "63", "ReferenceId": "22614000", "FullCitation": "Rizzo D, et al. Am. J. Surg. Pathol. (2012) pmid: 22614000", "Include": "true"}, {"number": "64", "ReferenceId": "23060122", "FullCitation": "Sullivan LM, et al. Mod. Pathol. (2013) pmid: 23060122", "Include": "true"}, {"number": "65", "ReferenceId": "23245672", "FullCitation": "Arnold MA, et al. Hum. Pathol. (2013) pmid: 23245672", "Include": "true"}, {"number": "66", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "67", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "68", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "69", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "70", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "71", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "72", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "73", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "74", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "75", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "76", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "77", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "78", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "79", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "80", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "81", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "82", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "83", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "84", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "85", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "86", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "87", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "88", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "89", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "90", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "91", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "92", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "93", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "94", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "95", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "96", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "97", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "98", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "99", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "100", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "101", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "102", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "103", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "104", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "105", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "106", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "107", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "108", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "109", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "110", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "111", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "112", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "113", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "114", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "115", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "116", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "117", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "118", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "119", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "120", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "121", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "122", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "123", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "124", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "125", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "126", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "127", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "128", "ReferenceId": "32546739", "FullCitation": "Chen FM, et al. Sci Rep (2020) pmid: 32546739", "Include": "true"}, {"number": "129", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "130", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "131", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "132", "ReferenceId": "27391784", "FullCitation": "Kawano S, et al. PLoS ONE (2016) pmid: 27391784", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_10_05 21:16:07", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "955x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 pca_score"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "NASOPHARYNX AND PARANASAL SINUSES", "disease_ontology": "Nasopharynx and paranasal sinuses undifferentiated carcinoma", "flowcell_analysis": "2000017969", "gender": "female", "pathology_diagnosis": "Sinonasal carcinoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.8.0", "purity_assessment": "40.0", "specimen": "ORD_1194451_01*US1158127.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1194451_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "961.79", "name": "SQ_US1158127.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5165", "cds_effect": "3856G>T", "depth": "1001", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "51.65", "position": "chr1:16256591", "protein_effect": "G1286W", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}, {"allele_fraction": "0.4592", "cds_effect": "521G>A", "depth": "895", "equivocal": "false", "functional_effect": "missense", "gene": "AKT1", "percent_reads": "45.92", "position": "chr14:105241459", "protein_effect": "R174H", "status": "unknown", "strand": "_", "transcript": "NM_001014431", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}, {"allele_fraction": "0.5098", "cds_effect": "2951C>T", "depth": "969", "equivocal": "false", "functional_effect": "missense", "gene": "ABL1", "percent_reads": "50.98", "position": "chr9:133760628", "protein_effect": "T984M", "status": "unknown", "strand": "+", "transcript": "NM_005157", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}, {"allele_fraction": "0.4593", "cds_effect": "569C>T", "depth": "1143", "equivocal": "false", "functional_effect": "missense", "gene": "SETD2", "percent_reads": "45.93", "position": "chr3:47165557", "protein_effect": "P190L", "status": "unknown", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}, {"allele_fraction": "0.5366", "cds_effect": "4071_4072insGATT", "depth": "382", "equivocal": "false", "functional_effect": "frameshift", "gene": "MSH6", "percent_reads": "53.66", "position": "chr2:48033987", "protein_effect": "K1358fs*2", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "CHEK2", "number_of_exons": "10 of 15", "position": "chr22:29092867_29130709", "ratio": "0.59", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "SMARCB1", "number_of_exons": "10 of 10", "position": "chr22:24075540_24248911", "ratio": "0.22", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1158127.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}